We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Faced with looming generic competition on many of its key products, as well as continuing uncertainty over its arthritis pain drugs, Pfizer has initiated a plan to trim annual costs by $4 billion within three years through such measures as plant closings, administrative cutbacks and sales force streamlining.
California lawmakers will soon take up a bill that would require drugmakers to pay the state a rebate for the costs of marketing life-saving drugs used in state assistance programs — a proposal critics say violates commercial free speech rights.
The widespread use of electronic data capture (EDC) technology is helping Novartis Pharmaceuticals cut down on errors during the clinical trial process and achieve research savings approaching $100 million annually.
Member companies of PhRMA invested a record $38.8 billion on pharmaceutical R&D in 2004, an increase of nearly 13 percent from the previous year, according to the trade group’s annual membership survey.
The pharmaceutical supply chain involves multiple organizations playing sometimes overlapping roles in product distribution and contracting, but drugmakers clearly have the most influence in establishing prices, according to a new report that explains the multistep path a drug takes from manufacturer to patient.
Aiming to rein in public spending on pharmaceuticals, California lawmakers will soon consider a bill that would require drugmakers to pay the state a rebate for costs of marketing life-saving drugs used in state assistance programs — a proposal that critics contend treads on commercial speech rights.
The barrage of negative news over drug safety has hurt the image of the pharmaceutical industry in the eyes of both consumers and physicians, but doctors also say the media have blown the issue out of proportion, a new poll finds.
The FDA is seeking advice on whether it should review and approve a new product that is labeled for use in conjunction with an existing product of a different type — an inquiry that indicates how the evolution of combination products is changing the regulatory landscape.
Advances in the biopharmaceutical sciences, including in the field of genomics, have given pharmaceutical firms vast amounts of new information on which to develop drugs — a key development that will fundamentally change the way drugmakers operate, industry experts say.